Advertisement

Identification a novel set of 6 differential expressed genes in prostate cancer that can potentially predict biochemical recurrence after curative surgery

  • F. Li
  • J.-P. Ji
  • Y. Xu
  • R.-L. Liu
Research Article
  • 2 Downloads

Abstract

Purpose

Approximately, 30% patients after radical prostatectomy (RP) will undergo post-operative biochemical recurrence (BCR). Present stratification method by TNM staging and Gleason score was not adequate to screen high-risk patients. In this study, we intended to identify a novel set of differentially expressed gene (DEG) signature that can predict BCR after RP.

Materials/patients

358 patients after RP with follow-up data were extracted from The Cancer Genome Atlas (TCGA), among which 61 patients had undergone BCR. Key DEGs were confirmed by the intersection of GSE35988 and TCGA_PCa dataset, and their gene expression data were also extracted from TCGA_PCa dataset. Kaplan–Meier plot and Cox proportion hazard regression model were applied to assess the relationship between risk score and survival outcome (BCR).

Results

310 DEGs were confirmed in two prostate cancer dataset. 6 DEGs (SMIM22, NINL, NRG2, TOP2A, REPS2, and TPCN2) were selected to construct a risk score formula. The risk score was a powerful predictive factor independent of TNM stage (HR 3.045, 95% CI 1.655–5.602, p < 0.001).

Conclusion

In this study, a novel 6-gene signature with robust predictive ability on post-operative BCR was constructed and 4 genes (SMIM22, NRG2, NINL and TPCN2) in the 6-gene signature were not reported to be associated with prostate cancer.

Keywords

Biomarker Recurrence Gene expression Prognosis Prostatic neoplasms 

Notes

Acknowledgements

This research was based on public database: TCGA, GEO and GEPIA, and we are grateful for the extraordinary works of these project groups. We thank Bioinformatics Engineer Rang-Fei Zhu for his excellent pretreatment of TCGA-PCa data.

Funding sources

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The patients’ information involved in our research was obtained from The Cancer Genome Atlas (TCGA). All the patients and treatments were complied with the principles laid down in the Declaration of Helsinki in 1964 and its later amendments or comparable ethical standards.

Informed consent

Informed consent was confirmed by all the patients participated in the TCGA-Prostate adenocarcinoma project.

References

  1. 1.
    Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630–42.CrossRefGoogle Scholar
  2. 2.
    Li D, Lv H, Hao X, et al. Prognostic value of serum alkaline phosphatase in the survival of prostate cancer: evidence from a meta-analysis. Cancer Manag Res. 2018;10:3125–39.CrossRefGoogle Scholar
  3. 3.
    Huang W, Su X, Yan W, et al. Overexpression of AR-regulated lncRNA TMPO-AS1 correlates with tumor progression and poor prognosis in prostate cancer. Prostate. 2018;78:1248–61.CrossRefGoogle Scholar
  4. 4.
    Zheng Y, Gao Y, Li X, et al. Long non-coding RNA NAP1L6 promotes tumor progression and predicts poor prognosis in prostate cancer by targeting Inhibin-beta A. Onco Targets Ther. 2018;11:4965–77.CrossRefGoogle Scholar
  5. 5.
    Albala D, Kemeter MJ, Febbo PG, et al. Health economic impact and prospective clinical utility of oncotype DX(R) Genomic Prostate Score. Rev Urol. 2016;18:123–32.Google Scholar
  6. 6.
    Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011;12:245–55.CrossRefGoogle Scholar
  7. 7.
    Karnes RJ, Choeurng V, Ross AE, et al. Validation of a genomic risk classifier to predict prostate cancer-specific mortality in men with adverse pathologic features. Eur Urol. 2018;73:168–75.CrossRefGoogle Scholar
  8. 8.
    Jiang Y, Mei W, Gu Y, et al. Construction of a set of novel and robust gene expression signatures predicting prostate cancer recurrence. Mol Oncol. 2018;12:1559–78.CrossRefGoogle Scholar
  9. 9.
    Martin NE. New developments in prostate cancer biomarkers. Curr Opin Oncol. 2016;28:248–52.CrossRefGoogle Scholar
  10. 10.
    Ross AE, D’Amico AV, Freedland SJ. Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer. Prostate Cancer Prostatic Dis. 2016;19:1–6.CrossRefGoogle Scholar
  11. 11.
    Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487:239–43.CrossRefGoogle Scholar
  12. 12.
    Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98–102.CrossRefGoogle Scholar
  13. 13.
    The Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell. 2015;163:1011–25.CrossRefGoogle Scholar
  14. 14.
    Li B, Ruotti V, Stewart RM, et al. RNA-Seq gene expression estimation with read mapping uncertainty. Bioinformatics. 2010;26:493–500.CrossRefGoogle Scholar
  15. 15.
    Thompson IM, Andriole GL, Blumenstein B, et al. AJCC cancer staging manual. 6th ed. New York: Springer; 2003.Google Scholar
  16. 16.
    Arredouani MS, Lu B, Bhasin M, et al. Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. Clin Cancer Res. 2009;15:5794–802.CrossRefGoogle Scholar
  17. 17.
    Reimand J, Arak T, Adler P, et al. g:profiler—a web server for functional interpretation of gene lists (2016 update). Nucleic Acids Res. 2016;44:W83–9.CrossRefGoogle Scholar
  18. 18.
    Huang TB, Dong CP, Zhou GC, et al. A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival. Int Urol Nephrol. 2017;49:825–35.CrossRefGoogle Scholar
  19. 19.
    Pathan M, Keerthikumar S, Ang CS, et al. FunRich: an open access standalone functional enrichment and interaction network analysis tool. Proteomics. 2015;15:2597–601.CrossRefGoogle Scholar
  20. 20.
    Molinari C, Matteucci F, Caroli P, et al. Biomarkers and molecular imaging as predictors of response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. Clin Colorectal Cancer. 2015;14:227–38.CrossRefGoogle Scholar
  21. 21.
    Polycarpou-Schwarz M, Gross M, Mestdagh P, et al. The cancer-associated microprotein CASIMO1 controls cell proliferation and interacts with squalene epoxidase modulating lipid droplet formation. Oncogene. 2018;37:4750–68.CrossRefGoogle Scholar
  22. 22.
    Ring HZ, Chang H, Guilbot A, et al. The human neuregulin-2 (NRG2) gene: cloning, mapping and evaluation as a candidate for the autosomal recessive form of Charcot-Marie-Tooth disease linked to 5q. Hum Genet. 1999;104:326–32.CrossRefGoogle Scholar
  23. 23.
    Dunn M, Sinha P, Campbell R, et al. Co-expression of neuregulins 1, 2, 3 and 4 in human breast cancer. J Pathol. 2004;203:672–80.CrossRefGoogle Scholar
  24. 24.
    Li J, Zhan Q. The role of centrosomal Nlp in the control of mitotic progression and tumourigenesis. Br J Cancer. 2011;104:1523–8.CrossRefGoogle Scholar
  25. 25.
    Nguyen ON, Grimm C, Schneider LS, et al. Two-pore channel function is crucial for the migration of invasive cancer cells. Cancer Res. 2017;77:1427–38.CrossRefGoogle Scholar
  26. 26.
    Oosterhoff JK, Penninkhof F, Brinkmann AO, et al. REPS2/POB1 is downregulated during human prostate cancer progression and inhibits growth factor signalling in prostate cancer cells. Oncogene. 2003;22:2920–5.CrossRefGoogle Scholar
  27. 27.
    Penninkhof F, Grootegoed JA, Blok LJ. Identification of REPS2 as a putative modulator of NF-kappaB activity in prostate cancer cells. Oncogene. 2004;23:5607–15.CrossRefGoogle Scholar
  28. 28.
    Oosterhoff JK, Kuhne LC, Grootegoed JA, et al. EGF signalling in prostate cancer cell lines is inhibited by a high expression level of the endocytosis protein REPS2. Int J Cancer. 2005;113:561–7.CrossRefGoogle Scholar
  29. 29.
    Badway JA, Baleja JD. Reps2: a cellular signaling and molecular trafficking nexus. Int J Biochem Cell Biol. 2011;43:1660–3.CrossRefGoogle Scholar
  30. 30.
    Schaefer-Klein JL, Murphy SJ, Johnson SH, et al. Topoisomerase 2 alpha cooperates with androgen receptor to contribute to prostate cancer progression. PLoS ONE. 2015;10:e0142327.CrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2019

Authors and Affiliations

  1. 1.Department of Urology, National Key Clinical Specialty of Urology, The Second Hospital of Tianjin Medical UniversityTianjin Medical UniversityTianjinChina
  2. 2.Department of UrologyRugao City People’s HospitalRugaoChina

Personalised recommendations